Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, March 24, 2023
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
[ Fri, Mar 24th 2023
] - WOPRAI
Leland Gershell Maintained (XFOR) at Buy with Decreased Target to $4 on, Mar 24th, 2023
Leland Gershell of Oppenheimer, Maintained "X4 Pharmaceuticals, Inc." (XFOR) at Buy with Decreased Target from $5 to $4 on, Mar 24th, 2023.
Leland has made no other calls on XFOR in the last 4 months.
There are 3 other peers that have a rating on XFOR. Out of the 3 peers that are also analyzing XFOR, 0 agree with Leland's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Leland
- Kristen Kluska of "Cantor Fitzgerald" Maintained at Buy and Held Target at $3 on, Wednesday, March 22nd, 2023
- Swayampakula Ramakanth of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $3 on, Wednesday, March 22nd, 2023
- Edward Tenthoff of "Piper Sandler" Initiated at Buy and Held Target at $3 on, Monday, December 12th, 2022
